Recently, Henlius announced the shipping of its independently developed and produced biosimilar trastuzumab, "Hanquyou," from the company's Songjiang base to the U.S. market. This marks the first commercial supply to North America and represents another significant breakthrough in the company's global strategic layout. With this, Henlius' commercial supply network has successfully expanded to regions including China, Southeast Asia, North America, Europe, the Middle East, and Latin America.

The international market expansion and high-quality development of Henlius are supported by the comprehensive lifecycle services provided by the Songjiang District. Leveraging the Shanghai Biomedical Registration Guidance Service Station, the district has proactively engaged to provide guidance and dedicated tracking, assisting biopharmaceutical companies like Henlius in accelerating drug research and production, which in turn promotes the vigorous development of the strategic emerging industrial cluster in Songjiang's biopharmaceutical sector.

Henlius's product portfolio covers areas such as oncology, autoimmune diseases, and ophthalmology, with six products approved in China, three in international markets, and 24 indications receiving approval. Four marketing applications have been accepted by the China National Medical Products Administration, the U.S. FDA, and the EU EMA.

https://finance.eastmoney.com/a/202412113264580423.html